Bioretec

0.02 EUR

+0.93 %

1,790 following

BRETEC

First North Finland

Medical Equipment & Services

Health Care

+0.93 %
+21.11 %
-19.87 %
-60.47 %
-67.95 %
-88.54 %
-89.51 %
-
-91.58 %

Bioretec operates in the medical technology sector. The company specializes in the development of medical technology products. The product portfolio includes, for example, implants for pediatric and adult orthopedics and other materials for bone and soft tissue injuries. In addition to the main business, service and related ancillary services are also offered. The business is operated globally with the largest presence in the Nordic region.

Read more
Market cap
29.25M EUR
Turnover
74.94K EUR
P/E (adj.) (26e)
-3.81
EV/EBIT (adj.) (26e)
-3.18
P/B (26e)
1.95
EV/S (26e)
4.38
Dividend yield-% (26e)
-
Coverage
Recommendation
Accumulate
Target price
0.02 EUR
Updated
17.05.2026
Disclaimer
Antti Siltanen
Antti Siltanen

Analyst

Latest research

Latest analysis report

Released: 18.05.2026

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
13.8
2026

Interim report Q2'26

12.11
2026

Business review Q3'26

Risk
Business risk
Valuation risk
Low
High
ShowingAll content types

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Forum discussions
Stock Exchange Release Bioretec Ltd - Managers’ Transactions - Paavola May 18, 2026 at 1:45 p.m. Person subject to the notification requirement Name: Tuukka Paavola Position: Chief Financial Officer (CFO) Nature of the transaction: ACQUISITION Transaction details (1): Volume: 500...
5/18/2026, 10:49 AM
by Index
15
That came right on cue!
5/18/2026, 7:48 AM
by BossoB
11
Here is the company report from Siltanen following Bioretec’s Q1 results. Bioretec’s Q1 results exceeded our expectations in terms of both revenue and earnings. Growth in the key markets of the United States and Europe offset the decline in the Rest of the World region, where the...
5/18/2026, 4:09 AM
by Sijoittaja-alokas
8
A 200 million euro balance sheet and a 100% equity ratio. His previous company, Picosun, was sold for hundreds of millions, which is the source of the company’s significant wealth.
5/21/2026, 7:40 AM
by Roni
7
Since biodegradable screws eliminate the need for removal surgery, it can be assumed that the number of complications will decrease, based on the premise that surgeries in general always carry a risk of complications. The US market operates primarily on a fee-for-service basis as...
5/22/2026, 12:59 PM
by Matti
4
Today’s newspaper Kaleva features an article on robotic surgery at OYS (Oulu University Hospital), and below is a screenshot from the piece. These are the reasons why, just over a year ago, Bioretec was the largest position in my portfolio and why I participated in last summer’s ...
5/22/2026, 12:16 PM
by Matti
3
@Antti_Siltanen, will there be an interview with Sarah van Hellenberg Hubar-Fisher regarding the Q1’26 report? I would love to hear about the situation described in Sarah’s own words in an interview .
5/18/2026, 6:38 AM
by Optimistinen verkkapöksy
3
Read more on our forum

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.